UCB

UCB, established in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. With a focus on neurology and immunology, UCB is committed to advancing science and delivering innovative solutions that enhance the lives of people with severe diseases. The company's robust research and development pipeline is driven by a dedication to understanding patient needs and delivering high-quality therapies.

Under the leadership of CEO Jean-Christophe Tellier, UCB has embraced a patient-centric approach, ensuring that every step from research to development is aligned with the ultimate goal of improving patient outcomes. The company leverages cutting-edge science and technology to discover and develop new medicines, while also optimising existing treatments. This approach has positioned UCB as a leader in the biopharmaceutical sector, particularly in the areas of neurology and immunology.

UCB's commitment to innovation is reflected in its ongoing investments in research and development, as well as its strategic partnerships with academic institutions and other industry leaders. The company employs approximately 9,000 people worldwide, all working towards the common goal of providing effective and sustainable healthcare solutions. By focusing on patient needs and leveraging its expertise in biopharmaceuticals, UCB continues to drive progress in the healthcare industry.